Pan-cancer analysis of oncogenic role of CEP55 and experiment validation in clear cell renal cell carcinoma

Q: What evidence links CEP55 to worse clinical outcomes across cancers?

CEP55 overexpression correlated with younger onset, advanced tumor stage, lower first-treatment response rates, and poorer OS/DFS across most analyzed cancers.

Q: How does CEP55 relate to proliferation pathways and molecular markers?

Enrichment analyses tied CEP55 to cell division, cell cycle activity, and proliferation, and expression correlated with proliferation markers such as MKI67 and PCNA as well as genes like KIF11, CDK1, and CCNA2.

Q: What did the study find about CEP55 and anti-PD-L1 immunotherapy response?

In the IMvigor210 cohort, CEP55 expression was significantly higher in patients achieving complete or partial remission compared with stable or progressive disease.

Sep 21, 2026

Uploaded by Eden

Immunotherapy is central to modern cancer treatment, yet CEP55’s oncogenic mechanisms and its prognostic and immunotherapy-predictive value across cancers remain unclear. CEP55 was overexpressed in 22 tumor types and linked with younger onset, advanced stage, poorer first-treatment response, and worse OS/DFS. CEP55 correlated with proliferation markers and cell-cycle pathways, associated with immune infiltration signatures, and related to MSI and TMB. In IMvigor210, higher CEP55 marked better CR/PR to anti-PDL1. Single-cell results in ccRCC showed poorer survival with CEP55-positive tumor epithelium, and wet-lab validation confirmed higher CEP55 positivity in tumors versus adjacent tissue, with clinical associations by size, grade and stage.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages15

Reading Time38 min

AccessFree to download

Background

Immunotherapy and need for immune biomarkers

CEP55 and its roles in cancer

Pan-cancer analysis results

Differential expression across cancer types

Clinical correlations with prognosis and treatment response

Pathway enrichment and proliferation markers

Immune infiltration and biomarkers (MSI/TMB)

ccRCC single-cell and clinical validation

Immune microenvironment implications in ccRCC

Wet-lab experimental verification

[www. nature.com/scientificreports](www. nature.com/scientificreports) OPEN Pan-cancer analysis of oncogenic role ofCEP55 and experiment validation in clear cell renal cell carcinoma Libin zhou1,2, Yimeng Zhu3, Fei Guo4, Huimin Long1,2􀀍 & Min Yin1,2􀀍 Immunotherapy has emerged as a vital component in the contemporary landscape of cancer treatment. Recent studies have indicated that CEP55 plays an oncogenic role; however, its specific mechanisms in promoting tumor proliferation and its potential value in prognosis and immunotherapy prediction across various cancers remain to be elucidated. CEP55 was significantly overexpressed in 22 cancer types compared with their adjacent normal tissues. Elevated CEP55 expression was positively correlated with younger onset age, worse tumor stage, lower response rate to the first treatment, lower tumor-free survival rate, and poorer overall survival (OS) and disease-free survival (DFS) prognosis in most cancers. Moreover, CEP55 expression was positively correlated with its binding and related genes, such as KIF11 (R = 0.83, P < 0.001), CDK1 (R = 0.77, P < 0.001) and CCNA2 (R = 0.76, P < 0.001), and the classic proliferation markers, including MKI67 and PCNA. Enrichment analyses indicated that CEP55 was predominantly associated with cell division, cell cycle activities and proliferation. Immune cell infiltration analysis by TIMER2.0 revealed that CEP55 expression was positively correlated with many kinds of infiltrating cells, such as Th2 cells and some CD4+ T cell subsets. The CEP55 expression was positively associated with increased MSI andTMB in various cancers. Our analyzation indicated that the CEP55 expression level in patients with complete remission (CR) or partial remission (PR) to anti-PDL1 therapy was significantly higher than patients with stable disease (SD) or progressive disease (PD) based on IMvigor210 cohort. We also used Gene Set Cancer Analysis (GSCA) to predict a serious of small molecule CEP55 targeted drugs, such as AZ628, SB52334, SB590885, A-770,041, AZD7762, Elesclomol, panobinostat, BRD-A94377914, and LRRK2-IN-1 . Furthermore, the patients with high level ofCEP55-posivie tumor epithelial cells had inferior overall survival in ccRCC according to single-cell analysis. Finally, our wet lab experiments verified that the CEP55-positive rate in ccRCC tissues (19/30, 63.3%) was significantly higher than that in renal adjacent tissues (10/30, 33.3%). The clinicopathologic analysis revealed that CEP55 protein level was significantly associated with tumor size (P = 0.044), histology grade (P < 0.001) and stage (P = 0.034) . Our study indicated that CEP55 overexpression in most caner types was associated with poor prognosis. Notably, CEP55 was closely relevant to immune cell infiltration and impacted the response to immunotherapy and small molecule drugs against cancers. Keywords CEP55, ccRCC, Pan-cancer analysis, Immune infiltration, Immunotherapy response, Proliferation markers Cancer has been one of the top killers worldwide, and the number of cancer patients continues to increase. Early diagnosis and targeted cancer therapies would help reduce cancer mortality1. Immunotherapy has been established as a pillar of cancer therapy improving the outcomes of a broad variety of cancers2. According to the comprehensive survey of the global immuno-oncology landscape, novel immunotherapies, including chimeric antigen receptor (CAR) T cell therapies, anti-PD1, anti-PDL1 or anti-CTLA4 monoclonal antibody, CD3- 1Department of Urology, The affiliated Lihuili Hospital of Ningbo University, Ningbo, Zhejiang, China. 2Department of Urology, Ningbo Medical Center Lihuili Hospital, Ningbo, Zhejiang, China. 3Department of Nephrology, Zhejiang University Medical College Affiliated Sir Run Run Shaw Hospital, Shaoxing, Zhejiang, China. 4Ningbo Institute of Innovation for Combined Medicine and Engineering (NIIME), Ningbo Medical Centre Lihuili Hospital, Ningbo, Zhejiang, China. 􀀍 email

FAQs

What evidence links CEP55 to worse clinical outcomes across cancers?

CEP55 overexpression correlated with younger onset, advanced tumor stage, lower first-treatment response rates, and poorer OS/DFS across most analyzed cancers.

How does CEP55 relate to proliferation pathways and molecular markers?

Enrichment analyses tied CEP55 to cell division, cell cycle activity, and proliferation, and expression correlated with proliferation markers such as MKI67 and PCNA as well as genes like KIF11, CDK1, and CCNA2.

What did the study find about CEP55 and anti-PD-L1 immunotherapy response?

In the IMvigor210 cohort, CEP55 expression was significantly higher in patients achieving complete or partial remission compared with stable or progressive disease.

Sep 21, 2026

Uploaded by Eden